Browse our 650+ Publications
Latest Publications
VJ Segment Usage of TCR-Beta Repertoire in Monozygotic Cystic Fibrosis Twins
Fischer S., et al.
Frontiers in Immunology
March 2021
Authors and Affiliates
Sebastian Fischer 1, Frauke Stanke 1,2 and Burkhard Tümmler 1,2;
1 Clinic for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany
2 Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research, Hannover Medical School, Hannover, Germany
Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
Olschewski V., et al.
Cancers
March 2021
Authors and Affiliates
Vito Olschewski 1,†, Hanno M. Witte 1,2,3,† , Veronica Bernard 4,†, Konrad Steinestel 3 , Wolfgang Peter 5,6, Hartmut Merz 4, Johannes Rieken 1, Harald Biersack 1, Nikolas von Bubnoff 1 , Alfred C. Feller 4 and Niklas Gebauer 1,*;
1 Department of Haematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany
2 Department of Hematology and Oncology, Federal Armed Forces Hospital Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
3 Institute of Pathology and Molecular Pathology, Federal Armed Forces Hospital of Ulm, Oberer Eselsberg 40, 89081 Ulm, Germany
4 Hämatopathologie Lübeck, Reference Center for Lymph Node Pathology and Hematopathology, 23562 Lübeck, Germany
5 HLA Typing Laboratory of the Stefan-Morsch-Foundation, 55765 Birkenfeld, Germany
6 Institute for Transfusion Medicine, University Hospital of Cologne, Kerpenerstr 62, 50937 Köln, Germany
* Author to whom correspondence should be addressed.
† These authors contributed equally to this manuscript.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Cascone T., et al.
February 2021
Authors and Affiliates
Tina Cascone 1, William N William Jr 2,3, Annikka Weissferdt 4,5, Cheuk H Leung 6, Heather Y Lin 6, Apar Pataer 5, Myrna C B Godoy 7, Brett W Carter 7, Lorenzo Federico 8, Alexandre Reuben 2, Md Abdul Wadud Khan 9, Hitoshi Dejima 10,11, Alejandro Francisco-Cruz 10, Edwin R Parra 10, Luisa M Solis 10, Junya Fujimoto 10, Hai T Tran 2, Neda Kalhor 4, Frank V Fossella 2, Frank E Mott 2, Anne S Tsao 2, George Blumenschein Jr 2, Xiuning Le 2, Jianjun Zhang 2, Ferdinandos Skoulidis 2, Jonathan M Kurie 2, Mehmet Altan 2, Charles Lu 2, Bonnie S Glisson 2, Lauren Averett Byers 2, Yasir Y Elamin 2, Reza J Mehran 5, David C Rice 5, Garrett L Walsh 5, Wayne L Hofstetter 5, Jack A Roth 5, Mara B Antonoff 5, Humam Kadara 10, Cara Haymaker 10, Chantale Bernatchez 8,10, Nadim J Ajami 12, Robert R Jenq 12,13,14, Padmanee Sharma 15,16, James P Allison 16, Andrew Futreal 12, Jennifer A Wargo 9, Ignacio I Wistuba 2,10, Stephen G Swisher 5, J Jack Lee 6, Don L Gibbons 2, Ara A Vaporciyan 5, John V Heymach #,2,17, Boris Sepesi #,5;
1 Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. tcascone@mdanderson.org.
2 Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3 Oncology Center, Hospital BP, a Beneficencia Portuguesa de São Paulo, São Paulo, Brazil.
4 Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5 Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
6 Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
7 Thoracic Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
8 Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
9 Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
10 Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
11 Teikyo University School of Medicine, Itabashi, Tokyo, Japan.
12 Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
13 Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
14 CPRIT Scholar in Cancer Research, Houston, TX, USA.
15 Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
16 Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
17 Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
# Contributed equally.
Role of the thymus in spontaneous development of a multi-organ autoimmune disease in human immune system mice
Khosravi-Maharlooei M, et al.
Journal of Autoimmunity
February 2021
Authors and Affiliates
Mohsen Khosravi-Maharlooei 1, HaoWei Li 1, Markus Hoelzl 1, Guiling Zhao 1, Amanda Ruiz 1, Aditya Misra 1, Yang Li 1, Nato Teteloshvili 1, Grace Nauman 1, Nichole Danzl 1, Xiaolan Ding 1, Elisha Y Pinker 1, Aleksandar Obradovic 1, Yong-Guang Yang 1, Alina Iuga 2, Remi J Creusot 1, Robert Winchester 3, Megan Sykes 4;
1 Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY, 10032, USA.
2 Department of Pathology, Columbia University Medical Center, Columbia University, New York, NY, 10032, USA.
3 Department of Pathology, Columbia University Medical Center, Columbia University, New York, NY, 10032, USA; Division of Rheumatology, Department of Medicine, Columbia University Medical Center, New York, NY, 10032, USA.
4 Columbia Center for Translational Immunology, Department of Medicine, Columbia University Medical Center, New York, NY, 10032, USA; Department of Microbiology & Immunology, Columbia University Medical Center, Columbia University, New York, NY, 10032, USA; Department of Surgery, Columbia University Medical Center, Columbia University, New York, NY, 10032, USA. Electronic address: megan.sykes@columbia.edu.
Single-cell analysis shows that adipose tissue of persons with both HIV and diabetes is enriched for clonal, cytotoxic, and CMV-specific CD4+ T cells
Wanjalla CN., et al.
February 2021
Authors and Affiliates
Celestine N. Wanjalla 1,2,5,14, Wyatt J. McDonnell 1,2,3,4,11, Ramesh Ram 10, Abha Chopra 10, Rama Gangula 15, Shay Leary 10, Mona Mashayekhi 6, Joshua D. Simmons 15, Christian M. Warren 15, Samuel Bailin 1, Curtis L. Gabriel 8, Liang Guo 12, Briana D. Furch 15, Morgan C. Lima 15, Beverly O. Woodward 15, LaToya Hannah 6, Mark A. Pilkinton 12, Daniela T. Fuller 12, Kenji Kawai 12, Renu Virmani 12, Aloke V. Finn 12, Alyssa H. Hasty 9,13, Simon A. Mallal 1,2,4,5,7,10, Spyros A. Kalams 1,2,4,5, John R. Koethe 1,2,5,13,15;
1 Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
2 Center for Translational Immunology and Infectious Disease, Vanderbilt University Medical Center, Nashville, TN, USA
3 Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA
4 Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN, USA
5 Tennessee Center for AIDS Research, Vanderbilt University Medical Center, Nashville, TN, USA
6 Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN, USA
7 VANTAGE, Vanderbilt University Medical Center, Nashville, TN, USA
8 Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University, Nashville, TN, USA
9 Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA
10 Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, Australia
11 10x Genomics, Pleasanton, CA, USA
12 CVPath Institute, Gaithersburg, MD, USA
13 Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA
Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients
Xydia M., et al.
Nature Communications
February 2021
Authors and Affiliates
Maria Xydia 1,2, Raheleh Rahbari 3, Eliana Ruggiero 4, Iain Macaulay 3,5, Maxime Tarabichi 3,6, Robert Lohmayer 7,8, Stefan Wilkening 4, Tillmann Michels 7, Daniel Brown 9,10, Sebastiaan Vanuytven 6,9, Svetlana Mastitskaya 11,12, Sean Laidlaw 3, Niels Grabe 11,13, Maria Pritsch 14, Raffaele Fronza 4, Klaus Hexel 15, Steffen Schmitt 15, Michael Müller-Steinhardt 16, Niels Halama 11,13, Christoph Domschke 17, Manfred Schmidt 4, Christof von Kalle 4,18, Florian Schütz 17, Thierry Voet 3,9, Philipp Beckhove 19,20;
1 RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. Maria.Xydia@ukr.de.
2 Translational Immunology Department, German Cancer Research Centre, Heidelberg, Germany. Maria.Xydia@ukr.de.
3 The Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute, Hinxton, UK.
4 Translational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre, Heidelberg, Germany.
5 Technical Development, Earlham Institute, Norwich, UK.
6 The Francis Crick Institute, London, UK.
7 RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany.
8 Institute for Theoretical Physics, University of Regensburg, Regensburg, Germany.
9 Department of Human Genetics, University of Leuven, KU Leuven, Leuven, Belgium.
10 The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
11 Medical Oncology Department, National Centre for Tumor Diseases, Heidelberg, Germany.
12 Centre for Cardiovascular and Metabolic Neuroscience, Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK.
13 Hamamatsu Tissue Imaging and Analysis Centre, BIOQUANT, University of Heidelberg, Heidelberg, Germany.
14 Translational Immunology Department, German Cancer Research Centre, Heidelberg, Germany.
15 Flow Cytometry Core Facility, German Cancer Research Centre, Heidelberg, Germany.
16 German Red Cross (DRK Blood Donation Service in Baden-Württemberg-Hessen) and Institute for Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
17 Department of Gynecology and Obstetrics, University Hospital of Heidelberg, Heidelberg, Germany.
18 Clinical Study Centre, Charité/BIH, Berlin, Germany.
19 RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg, Regensburg, Germany. beckhove@rcii.de.
20 Translational Immunology Department, German Cancer Research Centre, Heidelberg, Germany. beckhove@rcii.de.
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells
Duhen R., et al.
Nature Communications
February 2021
Authors and Affiliates
Rebekka Duhen 1, Carmen Ballesteros-Merino 2, Alexandra K Frye 2, Eric Tran 2, Venkatesh Rajamanickam 2, Shu-Ching Chang 3, Yoshinobu Koguchi 2, Carlo B Bifulco 2,4, Brady Bernard 2, Rom S Leidner 2, Brendan D Curti 2, Bernard A Fox 2, Walter J Urba 2, R Bryan Bell 2, Andrew D Weinberg 5,6;
1 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. rebekka.duhen@providence.org.
2 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
3 Medical Data Research Center, Providence Saint Joseph's Health, Portland, OR, USA.
4 Molecular Genomics Laboratory, Providence St. Joseph Health, Portland, OR, USA.
5 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. andrew.weinberg@providence.org.
6 AgonOx, Inc., Portland, OR, USA. andrew.weinberg@providence.org.
T Cell Repertoire Evolution after Allogeneic Bone Marrow Transplantation: An Organizational Perspective
Meier JA., et al.
Biology of Blood and Marrow Transplantation
February 2021
Authors and Affiliates
Jeremy A Meier 1, Mahdee Haque 1, Mohamed Fawaz 1, Hamdi Abdeen 1, David Coffey 2, Andrea Towlerton 2, Ahmed Abdeen 1, Abdullah Toor 1, Edus Warren 2, Jason Reed 3, Christopher G Kanakry 4, Armand Keating 5, Leo Luznik 6, Amir A Toor 7;
1 Bone Marrow Transplant Program, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia.
2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
3 Department of Physics, Virginia Commonwealth University, Richmond, Virginia.
4 Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
5 Princess Margaret Cancer Center, Toronto, Ontario, Canada.
6 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
7 Bone Marrow Transplant Program, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia. Electronic address: amir.toor@vcuhealth.org
In chronic infection, HIV gag-specific CD4+ T cell receptor diversity is higher than CD8+ T cell receptor diversity and is associated with less HIV quasispecies diversity
Pilkinton MA., et al.
Journal of Virology
February 2021
Authors and Affiliates
Mark A Pilkinton 1, Wyatt J McDonnell 1, Louise Barnett 1, Abha Chopra 2, Rama Gangula 1, Katie D White 1, Shay Leary 2, Jennifer Currenti 3, Silvana Gaudieri 1,2,3, Simon A Mallal 1,2,4, Spyros A Kalams 5,4;
1 Vanderbilt University Medical Center, Department of Internal Medicine, Nashville, TN 38232.
2 Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Australia.
3 School of Human Sciences, University of Western Australia, Nedlands, Australia.
4 Vanderbilt University School of Medicine, Department of Pathology, Microbiology and Immunology, Nashville, TN 38232.
5 Vanderbilt University Medical Center, Department of Internal Medicine, Nashville, TN 38232 s.kalams@vumc.org